Vallès, ErmengolJiménez, JesúsMartí-Almor, JulioToquero, JorgeOrmaetxe, José MiguelBarrera, AlbertoGarcía-Alberola, ArcadioRubio, José ManuelMoriña, PabloGrande, CarlosFé Arcocha, MariaPeinado, RafaelCózar, RocíoHernández, JulioPérez-Alvarez, LuisaGaztañaga, LarraitzFerrero-De Loma-Osorio, AngelRuiz-Granell, RicardoVilluendas, RogerMartínez-Alday, Jesús Daniel2023-05-032023-05-032022-02-222077-0383http://hdl.handle.net/10668/21243Introduction: Cryoballoon ablation (CBA) has become a standard treatment for paroxysmal atrial fibrillation (PaAF) but limited data is available for outcomes in patients with persistent atrial fibrillation (PeAF). Methods: We analyzed the first 944 patients included in the Spanish Prospective Multi-center Observation Post-market Registry to compare characteristics and outcomes of patients undergoing CBA for PeAF versus PaAF. Results: A total of 944 patients (57.8 ± 10.4 years; 70.1% male) with AF (27.9% persistent) were prospectively included from 25 centers. PeAF patients were more likely to have structural heart disease (67.7 vs. 11.4%; penAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/cryoballoon procedurepersistent atrial fibrillationregistryresearch article35268259open access10.3390/jcm11051166PMC8910954https://www.mdpi.com/2077-0383/11/5/1166/pdf?version=1645531741https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8910954/pdf